Population Pharmacokinetics and Dose Evaluation of Cycloserine among Patients with Multidrug-Resistant Tuberculosis under Standardized Treatment Regimens
Yue Zhu, Limei Zhu, Lina Davies Forsman, Jakob Paues, Jim Werngren, Katarina Niward, Thomas Schön, Judith Bruchfeld, et al. (11 authors)
Antimicrobial Agents and Chemotherapy · 2023-04
Abstract
Although cycloserine is a recommended drug for the treatment of multidrug-resistant tuberculosis (MDR-TB) according to World Health Organization (WHO), few studies have reported on pharmacokinetics (PK) and/or pharmacodynamics (PD) data of cycloserine in patients with standardized MDR-TB treatment. This study aimed to estimate the population PK parameters for cycloserine and to identify clinically relevant PK/PD thresholds, as well as to evaluate the current recommended dosage.
MeSH terms
- Cycloserine
- Medicine
- Pharmacokinetics
- Pharmacodynamics
- Dosing
- Population
- Pharmacology
- Tuberculosis
- Internal medicine
- Sputum
- Area under the curve